Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diazepam - Aquestive Therapeutics

Next Previous
X
Search
Drug Profile

Diazepam - Aquestive Therapeutics

Alternative Names: AQST-203; DBF; DBSF; Diazepam BSF; Diazepam buccal soluble film - Aquestive Therapeutics; Libervant

Latest Information Update: 21 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MonoSol Rx
  • Developer Aquestive Therapeutics
  • Class Antiepileptic drugs; Anxiolytics; Benzodiazepines; Benzodiazepinones; Hypnosedatives; Muscle relaxants; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Seizures
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Seizures
  • Phase III Epilepsy

Most Recent Events

  • 14 Jan 2025 Aquestive Therapeutics announces intention to submit NDA and launch diazepam in Epilepsy
  • 06 Aug 2024 Aquestive Therapeutics plans to file for approval of Libervant for Epilepsy (In children)
  • 29 Apr 2024 Registered for Seizures (In children) in USA (Buccal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top